Green Yellow Holding generates electricity from centralized power plants and offers solar panels. The company allows anyone to produce and manage energy while creating value, through solar photovoltaics, efficiency, and energy optimization.
Beta Bionics is a biotechnology company that develops an integrated bionic pancreas system called the iLet. The iLet Bionic Pancreas System was granted breakthrough designation in all configurations (insulin-only, glucagon-only, and bihormonal), including use with Zealand Pharma’s dasiglucagon, a glucagon analogue with a stability profile in a ready-to-use aqueous solution. It also offers a bionic pancreas device for glucose metabolism to the diabetes community.
Ada is a global health company founded by doctors, scientists, and industry pioneers to create new possibilities for personal health. Ada’s core system connects medical knowledge with intelligent technology to help all people actively manage their health and medical professionals to deliver effective care. Ada is proud to collaborate with leading health systems and global non-profit organizations to carry out this vision. Ada Health was founded in 2011 and is based in Berlin, Germany.
DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. Their revolutionary enzymatic technology powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results.
Hibob was founded to modernize HR tech. Hibob's intuitive and data-driven platform, Bob, was built for the way people work today: globally, remotely, and collaboratively. Since its launch in late 2015, Bob has achieved consecutive triple-digit year-over-year growth and become the HRIS of choice for more than 1,000 modern, midsize, and multinational companies that understand that a powerful, agile HR tech suite is mission critical and a key driver of organizational success. Fast-growing companies across the globe such as Monzo, Happy Socks, Gong, Fiverr, and VaynerMedia rely upon Bob to help HR and managers connect, engage, develop, and retain top talent. Learn more at www.hibob.com
Swift Health Systems is a stealth stage medical device company developing INBRACE: a revolutionary, easy to use, wide indication, personalized orthodontic system hidden behind the teeth. Our patented self-guiding technology uses light and continuous forces to gently correct your smile with less pain and fewer doctor visits. INBRACE is FDA registered and a catalyst for disruption in orthodontics. INBRACE increases the number of people who will seek orthodontic treatment by addressing the top concerns for patients while driving practice growth for clinicians. Our platform leverages digital treatment planning, computer modeling, and direct digital manufacturing to create a scalable, patient customized solution that delivers the standard of care across the entire range of orthodontic cases.
SomaLogic operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscan technology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions. SomaLogic was founded in 1999 and is headquartered in Boulder, Colorado.
Zepz operates WorldRemit, an online platform that facilitates international money transfers, allowing users to send funds to friends and family abroad. Established in 2009 and headquartered in London, WorldRemit provides a secure service accessible via computer, smartphone, or tablet. The platform enables users to send money to over 140 destinations, including countries in Africa, Asia, Europe, and the Americas. Recipients can receive funds through various methods, such as bank deposits, cash pickups, mobile money, and airtime top-ups. By offering a convenient and low-cost alternative to traditional money transfer services, WorldRemit has become a popular choice for millions of users looking to support their loved ones and manage their financial transactions effectively.
Zentera Therapeutics is a biopharmaceutical company.
POINT Biopharma Global Inc. is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer. POINT Biopharma Global Inc. is combining a portfolio of best-in-class radiopharmaceutical assets, a seasoned management team, expertise in radioisotopes such as Actinium-225 (Ac-225) and Lutetium-177 (Lu-177), manufacturing technology and novel direct-to-patient targeting to revolutionize theragnostic drug development and radioligand commercialization.
Our mission is to transform research and diagnostics with an affordable, scalable genomic sequencing ecosystem. We believe in providing innovative sequencing solutions and high-quality service to our customers and partners. We lead with integrity and resiliency. We promise our stakeholders transparency, inclusivity and collaboration. It was founded in 2010 and headquartered in Redwood City, California.
Biotheryx is a clinical stage biopharmaceutical company discovering and developing a portfolio of innovative small molecule targeted protein degraders (TPDs) for the treatment of a wide range of diseases with an initial focus on cancer. Members of our founding and scientific teams previously developed the first FDA approved modulators of Cereblon, the most widely validated E3 ligase involved in protein degradation, and have applied their expertise in Cereblon binding to build our proprietary PRODEGY platform. Our platform leverages an extensive patent protected and rationally designed library of Cereblon binders that we believe provides us with a differentiated starting point for drug design of molecular glues, bifunctional degraders and hybrid degraders.
NeoGenomics is a cancer reference laboratory that provides cancer testing and partnership programs to pathologists and oncologists. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia.
Exscientia combines human expertise with AI and machine learning to enhance drug discovery. The company focuses on precision engineering of medicine candidates, enabling faster and more efficient development of new treatments. By integrating innovative experimental techniques, Exscientia aims to improve patient outcomes and revolutionize the pharmaceutical industry.
LUMICKS delivers state-of-the-art technologies for the study of biology and cancer at the single-molecule and single-cell levels. It aims to build the unfinished bridge between structure and function at the molecular and cellular levels. Using its product C-Trap Optical Tweezers, Fluorescence Microscopy, scientists are able to analyze complex biological processes in real-time. Similarly, the z-Movi Cell Avidity Analyzer enables the measurement and selection of immune cells based on their real-time interactions with target cells.
Theseus Pharmaceuticals is a technology-based company.
Orchard Therapeutics is a fully integrated commercial-stage company dedicated to treating the lives of patients with rare diseases through innovative gene therapies. Orchard’s portfolio of autologous ex vivo gene therapy programs has demonstrated sustained clinical benefit in over 150 patients across five disease areas. These programs include Strimvelis®, the first autologous ex vivo gene therapy approved by the EMA in 2016, 3 programs in advanced registrational studies in MLD (metachromatic leukodystrophy), WAS (Wiskott-Aldrich syndrome), and ADA-SCID (adenosine deaminase severe combined immunodeficiency), 2 other clinical programs in X-CGD (X-linked chronic granulomatous disease) and beta-thalassemia, as well as an extensive preclinical pipeline. The company is partnered with world-leading institutions in gene therapy, including University College London, Great Ormond Street Hospital, the University of Manchester and Central Manchester University Hospitals, the University of California Los Angeles and Boston Children’s Hospital, and Telethon Institute of Gene Therapy/Ospedale San Raffaele.
Inivata is a clinical cancer genomics company harnessing the emerging potential of circulating DNA analysis to improve testing and treatment for oncologists and their patients. Unlike conventional invasive biopsies, Inivata detects and analyses genomic material from a cancer patient’s cell-free, circulating tumor DNA (ctDNA) which can be collected through a simple blood sample. This non-invasive approach – a liquid biopsy – offers a revolution in how cancer is detected, monitored, and treated.
DarioHealth is a digital health company. It is engaged in the development and commercialization of patented and proprietary technology that provides consumers with laboratory-testing capabilities using smartphones and other mobile devices. The company's product, Dario Blood sugar monitor is a mobile, real-time, cloud-based, diabetes management solution based on a multi-featured software application combined with a blood glucose monitoring device. The group operates internationally and derives revenues from the sale of its Dario smart meter and related device-specific disposables test strip cartridges and lancets. The company generates the majority of the revenue.
Beam Therapeutics is a biotechnology company engaged in creating genetic medicines based on its base editing technology. It is pioneering the use of base editing, a potential new class of precision genetic medicines, with a vision of providing life-long cures to patients suffering from serious diseases. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the dna.
Ikena Oncology discovers and develops biomarker-driven therapies for cancer patients. The company focuses on developing novel cancer therapies that drive the formation and spread of cancer. Ikena Oncology provides medical needs by discovering chemistry, translational science, and patient-centric drug development.
FogPharma was born from the scientific and entrepreneurial vision of founder Greg Verdine, a pioneer in the discovery and development of new drug classes that “drug the undruggable.” FogPharma’s cell-penetrating mini proteins (CPMPs) are a broad new class of medicines that can drug targets beyond the reach of conventional therapeutics. Together with world-leading experts and collaborators in cancer biology and therapy, our team is building a drug discovery powerhouse having passion, knowledge, and creativity to develop fundamentally new cancer treatments. FogPharma derives financial support from a unique syndicate of extraordinary private and institutional investors. FogPharma’s network of friends includes our founders, employees, investors, advisors, collaborators, and cancer patients; all working together to pioneer a unique approach toward conquering cancer. It is laser-focused and unstoppable in its mission to deliver a new class of medicines to patients and their families to bring them years to life and life to years.
Univercells is a One-stop-shop for high-density low-cost biomanufacturing "end-to-end" solutions, with innovative engineering able to decrease the needs for investments of over 75% and the cost of goods of up to 90%. Univercells' technologies, aimed at low cost manufacturing of antibodies/proteins/vaccines, is based on single-use technologies, and chaining of three manufacturing steps into simulated continuous mode : cell culture under perfusion, clarification and capture.
SomaLogic operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscan technology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions. SomaLogic was founded in 1999 and is headquartered in Boulder, Colorado.
Longboard Pharmaceuticals delivers medicines with optimized pharmacology and pharmacokinetics to patients with rare neurological diseases. Its proprietary pipeline includes multiple programs with broad clinical utility. Longboard is evaluating LP352, a next-generation 5-HT2C agonist, in development for the potential treatment of developmental and epileptic encephalopathies, or DEEs. Longboard is also evaluating LP143, a centrally acting, full agonist of the cannabinoid type 2 receptor (CB2), and LP659, a centrally acting, next-generation, highly selective S1P receptor modulator.
Clinical-stage biotech focused on cardiovascular, central nervous system, inflammatory and metabolic diseases. Their leading drug candidate is lorcaserin hydrochloride, which recently received positive data from a clinical trial. They are headquartered in San Diego, CA.
AUTO1 Group is a used-car marketplace with its own certified and diversified inventory and a technology platform that allows buyers and sellers. AUTO1 is aimed primarily at the used car trade. By connecting buyers and sellers through technology the company enables consumers as well as dealers to trade seamlessly. Sourcing from all channels including OEMs and dealerships. AUTO1 Group owns business units like AUTO1.com, Autohero.com or wirkaufendeinauto.de. AUTO1 Group operates in almost 30 countries and continues to expand rapidly.
Encoded Therapeutics is a developer of precision gene therapies intended to provide treatment for a broad range of severe genetic disorders. The company's therapy pipeline addresses devastating genetic and acquired disorders spanning multiple disease pathways including neurocircuitry, metabolic disorders, neurodegeneration and cardiovascular disease, enabling medical practitioners to treat patients and improve their lives.
BioAtla, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, specializing in the development of specific and selective antibody-based therapeutics for cancer treatment. The company utilizes its proprietary platforms, Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!), to create novel monoclonal antibody and cell-based therapeutics. Its lead product candidate, BA3011, is a conditionally active biologic antibody-drug conjugate aimed at treating soft tissue and bone sarcoma, non-small cell lung cancer, and other tumors. BioAtla's pipeline also includes BA3021, targeting non-small cell lung cancer and melanoma, and BA3071, which addresses various cancers such as renal cell carcinoma and bladder cancer. The company's innovative approach enhances drug selectivity for cancer tissues, potentially improving safety and expanding treatment options for previously untreatable cancers. BioAtla holds over 150 issued patents and patent applications, underscoring its commitment to developing safer and more effective cancer therapies.
Annexon is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye. The company’s pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. The company’s first product candidate, ANX005, is a full-length monoclonal antibody formulated for intravenous administration in autoimmune and neurodegenerative disorders. The company’s second product candidate, ANX007, is a monoclonal antibody Fab formulated for intravitreal administration for the treatment of neurodegenerative ophthalmic disorders. Annexon is advancing its current programs while evaluating additional orphan and large market indications. Annexon is deploying a disciplined, biomarker-driven development strategy designed to establish that its product candidates are engaging the target at a well-tolerated therapeutic dose in the intended patient tissue.
Private Equity Round in 2020
Atento provides customer relationship management and business process outsourcing services. Their services include customer care, sales, collections, back office, and technical support services. Their clients are in sectors including telecommunications, banking and financial services, health, retail, and public administration.
CargoX is a technology freight marketplace that provides shipping companies and carriers a smart and efficient solution to transport the most diverse types of products in any parts of LATAM. Through technology, we connect over 10 thousand shippers with 1.4 million trucks to eliminate excess capacity. CargoX save on shipping costs for shippers, increase earnings for truckers and reduces C02 emissions generated by empty trucks on the road.
Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins that it is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC. Pliant is currently recruiting two Phase 2a trials of PLN-74809 for the treatment of IPF and plans to initiate a Phase 2a trial in PSC in the second half of 2020. Pliant's second product candidate, PLN-1474, is a small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis, or NASH, which Pliant has partnered with Novartis. PLN-1474 is currently undergoing a Phase 1 trial. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies.
Generation Bio is an innovative genetic medicines company focused on creating a new class of gene therapy to provide durable, redosable treatments for patients suffering from both rare and prevalent diseases. The company’s non-viral platform incorporates a proprietary high-capacity DNA construct called closed-ended DNA, or ceDNA; a novel cell-targeted lipid nanoparticle delivery system, or ctLNP; and an established, scalable capsid-free manufacturing process. The company is designing therapies to provide targeted delivery of genetic payloads that include large and multiple genes across a broad array of tissues, and to be redosable for individualized and extended treatment throughout a patient’s life. The platform is designed to expand access to treatments for rare diseases and to address prevalent diseases through efficient, scalable manufacturing.
Themis Bioscience is a start-up biotechnology company developing vaccines to prevent infectious diseases. The company’s development focus is primarily concentrated on emerging and specialist indications, advancing promising vaccines from preclinical to late-stage clinical development phases. We aim to exploit the increasing licensing and acquisition trend to generate value by developing and partnering our technology programs and vaccine candidates. It is our mission to establish Themis as a first class biotech development boutique and to become a preferred licensing partner for leading biotech and pharmaceutical companies.
Beta Bionics is a biotechnology company that develops an integrated bionic pancreas system called the iLet. The iLet Bionic Pancreas System was granted breakthrough designation in all configurations (insulin-only, glucagon-only, and bihormonal), including use with Zealand Pharma’s dasiglucagon, a glucagon analogue with a stability profile in a ready-to-use aqueous solution. It also offers a bionic pancreas device for glucose metabolism to the diabetes community.
Advance Intelligence Group is a financial technology firm that builds an ecosystem of AI-powered, credit-enabled products, and services. Founded in 2016, it leverages innovative technology and partnerships to build an ecosystem of products and services serving consumers, enterprises, and merchants.
Private Equity Round in 2018
Full Truck Alliance is a platform that connects shippers with truckers to facilitate shipments across distance ranges and cargo weights. its revenues principally from shippers' and truckers' use of its platforms in connection with freight matching services.
Meituan Bike (formerly Mobike) is a Chinese fully station-less bicycle-sharing system. It develops mobile apps for users to find and use bicycles to travel anywhere. Davis Wang Xiao Feng, Hu Wei Wei, and Xia Yi Ping founded Mobike on January 27, 2015, with its headquarters in Beijing, China. Mobike raised $600 million in Series E funding led by Tencent, bringing the firm's fundraising in 2017 alone to nearly US$1 billion in June 2017. It became worth US$3 billion in the same month. Chinese web company Meituan-Dianping acquired Mobike for US$2.7 billion in April 2018. Parent company Meituan-Dianping announced name change from Mobike to Meituan Bike on January 23, 2019 as part of an ongoing integration.
Sea is a consumer internet company. The company's mission is to improve the lives of consumers and small businesses in the region with technology. The company's businesses include Shopee, Garena, and SeaMoney.
The renewable energy arm of Hindustan Power Projects Pvt. Ltd .
Gojek is an app that providing a variety of services from payments, food delivery, transportation, and logistics. The app is used for food ordering, commuting, digital payments, shopping, hyper-local delivery, getting a massage, and other services. It aims to create a positive socio-economic impact on customers, driver-partners, business, and MSMEs. Gojek is backed by investors including Google, Facebook, PayPal, Sequoia Capital, and Tencent Holdings. The company was founded in 2009 in Jakarta, Jakarta Raya, Indonesia by Kevin Aluwi, Nadiem Makarim, and Michaelangelo Moran.
Our mission is to be a revolutionary force in the growing US$25 billion global animal pharmaceutical market. Only Nexvet can produce therapeutic antibodies that are 100% customised to target new species – like cats and dogs. Monoclonal antibody therapies have represented a new generation of highly effective, safe and targeted medicines in humans. We think it’s time companion animals reaped the benefits of human medical progress in this field. Nexvet’s unique technology, PETisation™, ensures 100% customisation of a therapy to a new species, reducing the chances of immune challenges, and ensuring a more ‘natural’ fit between the therapy and the patient. Many chronic conditions in pets remain poorly treated by current veterinary therapies, such as pain and various inflammatory diseases– which has guided Nexvet’s focus towards these indications. To ensure we succeed in transforming animal medicine, we’ve brought together a team with an extraordinary global track record in animal and human health. We are working with leading contractors, advisors, drug development partners, academic groups, veterinarians and animal interest groups around the world to develop our pipeline to the highest standards. Senior executives and researchers from the world’s largest animal health brands are counted among our Board, management, and advisors, and together we’re building connections worldwide to make our vision a reality.
Intarcia Therapeutics is a biopharmaceutical company that develops therapies for diseases that require long-term chronic treatment. It offers DUROS, a drug delivery platform that stabilizes and delivers therapeutic proteins and peptides. Intarcia Therapeutics' products include OMEGA DUROS, an interferon delivery device for treating Hepatitis C and ITCA 650, a delivery device that provides type 2 diabetes patients with long-term steady state dosing of an incretin mimetic therapy. Additionally, it develops programs for treating obesity. David Franklin, James M. Ahlers, and Thomas Alessi founded BioMedicines in 1997 that became Intarcia Therapeutics in September 2004. Its headquarters is in Hayward in California with an additional office in Mountain View in California.
Intarcia Therapeutics is a biopharmaceutical company that develops therapies for diseases that require long-term chronic treatment. It offers DUROS, a drug delivery platform that stabilizes and delivers therapeutic proteins and peptides. Intarcia Therapeutics' products include OMEGA DUROS, an interferon delivery device for treating Hepatitis C and ITCA 650, a delivery device that provides type 2 diabetes patients with long-term steady state dosing of an incretin mimetic therapy. Additionally, it develops programs for treating obesity. David Franklin, James M. Ahlers, and Thomas Alessi founded BioMedicines in 1997 that became Intarcia Therapeutics in September 2004. Its headquarters is in Hayward in California with an additional office in Mountain View in California.
Intarcia Therapeutics is a biopharmaceutical company that develops therapies for diseases that require long-term chronic treatment. It offers DUROS, a drug delivery platform that stabilizes and delivers therapeutic proteins and peptides. Intarcia Therapeutics' products include OMEGA DUROS, an interferon delivery device for treating Hepatitis C and ITCA 650, a delivery device that provides type 2 diabetes patients with long-term steady state dosing of an incretin mimetic therapy. Additionally, it develops programs for treating obesity. David Franklin, James M. Ahlers, and Thomas Alessi founded BioMedicines in 1997 that became Intarcia Therapeutics in September 2004. Its headquarters is in Hayward in California with an additional office in Mountain View in California.
Youku is a Chinese video-sharing website that enables users to search, view, and share high-quality video content across multiple devices. Employing the tri-networks integration model, Youku’s online video content ranges from user-generated content and self-produced serials to licensed professional content. Its platform offers a space for individuals and institutions to upload and share their treasured moments, independent films, viral videos, and other creations. Youku was first listed on the New York Stock Exchange on December 18, 2010. As of 2007, the company had raised over $40 million in funds, which came from existing investors, including Maverick Capital, Brookside Capital (an affiliate of Bain Capital, LLC), Sutter Hill Ventures, Farallon Capital, and China-based Chengwei Ventures, LLC. In the same year, AC Nelson Co. announced that Youku's overall video viewing (VV) rate had exceeded 100 million, and the daily UV rate exceeded 12 million. On March 12, 2012, Youku reached an agreement to acquire Tudou in a stock-for-stock transaction, the new entity being named Youku Tudou, Inc. Youku's major competitors include Tencent Video, 163 Video, and Sohu Video.
Sohu provides a network of community-based, web 2.0 products to millions of Chinese users on a daily basis. Sohu corporate services consist of online brand advertising on its matrix of websites as well as bid listing and home page on its in-house developed search directory and engine. This matrix of Chinese language web properties and proprietary search engines, consists of the mass portal and online media destination sohu.com, interactive search engine sogou.com, the games information portal 17173.com, the real estate website focus.cn, developer and operator of online games www.changyou.com/en/ and online video website tv.sohu.com. It also provides multiple news and information service on mobile platforms, including Sohu News app and mobile news portal WAP.Sohu.com. Sohu's online game subsidiary, Changyou.com has a diverse portfolio of online games that includes Tian Long Ba Bu, a massively multiplayer online games in China, and DDTank and Wartune (also known as Shen Qu), which are two popular web games in China. Sohu.com was established in November 1995 and went public in July 2000.
AdsIt is an online video advertisement provider based in Beijing, China.
Beijing Adsit Media Technology Co., Ltd. (随视传媒) is a Chinese distribution platform for internet-based video advertisements. It is not only the operating company and technology service provider of Baidu TV business model, but also the only strategic brand management partner in the history of Baidu because of its innovative technological advantages and its customized online video advertising service platform for advertising agency companies.
Youku is a Chinese video-sharing website that enables users to search, view, and share high-quality video content across multiple devices. Employing the tri-networks integration model, Youku’s online video content ranges from user-generated content and self-produced serials to licensed professional content. Its platform offers a space for individuals and institutions to upload and share their treasured moments, independent films, viral videos, and other creations. Youku was first listed on the New York Stock Exchange on December 18, 2010. As of 2007, the company had raised over $40 million in funds, which came from existing investors, including Maverick Capital, Brookside Capital (an affiliate of Bain Capital, LLC), Sutter Hill Ventures, Farallon Capital, and China-based Chengwei Ventures, LLC. In the same year, AC Nelson Co. announced that Youku's overall video viewing (VV) rate had exceeded 100 million, and the daily UV rate exceeded 12 million. On March 12, 2012, Youku reached an agreement to acquire Tudou in a stock-for-stock transaction, the new entity being named Youku Tudou, Inc. Youku's major competitors include Tencent Video, 163 Video, and Sohu Video.
Youku is a Chinese video-sharing website that enables users to search, view, and share high-quality video content across multiple devices. Employing the tri-networks integration model, Youku’s online video content ranges from user-generated content and self-produced serials to licensed professional content. Its platform offers a space for individuals and institutions to upload and share their treasured moments, independent films, viral videos, and other creations. Youku was first listed on the New York Stock Exchange on December 18, 2010. As of 2007, the company had raised over $40 million in funds, which came from existing investors, including Maverick Capital, Brookside Capital (an affiliate of Bain Capital, LLC), Sutter Hill Ventures, Farallon Capital, and China-based Chengwei Ventures, LLC. In the same year, AC Nelson Co. announced that Youku's overall video viewing (VV) rate had exceeded 100 million, and the daily UV rate exceeded 12 million. On March 12, 2012, Youku reached an agreement to acquire Tudou in a stock-for-stock transaction, the new entity being named Youku Tudou, Inc. Youku's major competitors include Tencent Video, 163 Video, and Sohu Video.
E-House is a real estate services company in China offering a comprehensive online-to-offline (O2O) service platform. It offers primary sales agency services, online real estate services, real estate information and consulting services, real estate advertising services, real estate promotional event services, secondary real estate brokerage services, and real estate investment fund management services. E-House has served more than 80% of domestic real estate developers, including Vanke, Evergrande, Wanda, Longfor, Poly Real Estate, and many other real estate industry giants, and worked on more than 200,000 real estate projects. E-House was founded in 2004 and was first listed on the New York Stock Exchange in August 2007.
Heidi Coast Advertising Co., Ltd. is a Chinese company focused on the development and operation of campus media integrated marketing solutions. Heidi Coast Advertising’s leading brand, “China Campus Media,” covers new media such as campus video, campus outdoor, campus activity, CC176.com, and more. By cooperating with educational institutions and major domestic media organizations, the company spreads news, entertainment, programs, and advertisement information in universities and colleges, with students as the main audience group. It covers 18 economically developed cities and over 330 colleges and universities in China. It influences over 5 million people daily and maintains a campus broadcasting network.
Youku is a Chinese video-sharing website that enables users to search, view, and share high-quality video content across multiple devices. Employing the tri-networks integration model, Youku’s online video content ranges from user-generated content and self-produced serials to licensed professional content. Its platform offers a space for individuals and institutions to upload and share their treasured moments, independent films, viral videos, and other creations. Youku was first listed on the New York Stock Exchange on December 18, 2010. As of 2007, the company had raised over $40 million in funds, which came from existing investors, including Maverick Capital, Brookside Capital (an affiliate of Bain Capital, LLC), Sutter Hill Ventures, Farallon Capital, and China-based Chengwei Ventures, LLC. In the same year, AC Nelson Co. announced that Youku's overall video viewing (VV) rate had exceeded 100 million, and the daily UV rate exceeded 12 million. On March 12, 2012, Youku reached an agreement to acquire Tudou in a stock-for-stock transaction, the new entity being named Youku Tudou, Inc. Youku's major competitors include Tencent Video, 163 Video, and Sohu Video.